Literature DB >> 33536571

Arrayed CRISPR reveals genetic regulators of tau aggregation, autophagy and mitochondria in Alzheimer's disease model.

Lishu Duan1, Mufeng Hu2, Joseph A Tamm3, Yelena Y Grinberg3, Fang Shen3, Yating Chai2, Hualin Xi3, Lauren Gibilisco2, Brinda Ravikumar3, Vivek Gautam3, Eric Karran3, Matthew Townsend3, Robert V Talanian3.   

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease with poor prognosis. New options for drug discovery targets are needed. We developed an imaging based arrayed CRISPR method to interrogate the human genome for modulation of in vitro correlates of AD features, and used this to assess 1525 human genes related to tau aggregation, autophagy and mitochondria. This work revealed (I) a network of tau aggregation modulators including the NF-κB pathway and inflammatory signaling, (II) a correlation between mitochondrial morphology, respiratory function and transcriptomics, (III) machine learning predicted novel roles of genes and pathways in autophagic processes and (IV) individual gene function inferences and interactions among biological processes via multi-feature clustering. These studies provide a platform to interrogate underexplored aspects of AD biology and offer several specific hypotheses for future drug discovery efforts.

Entities:  

Year:  2021        PMID: 33536571     DOI: 10.1038/s41598-021-82658-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  56 in total

Review 1.  The Cellular Phase of Alzheimer's Disease.

Authors:  Bart De Strooper; Eric Karran
Journal:  Cell       Date:  2016-02-11       Impact factor: 41.582

Review 2.  The biology of proteostasis in aging and disease.

Authors:  Johnathan Labbadia; Richard I Morimoto
Journal:  Annu Rev Biochem       Date:  2015-03-12       Impact factor: 23.643

3.  Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study.

Authors:  Ralph A Nixon; Jerzy Wegiel; Asok Kumar; Wai Haung Yu; Corrinne Peterhoff; Anne Cataldo; Ana Maria Cuervo
Journal:  J Neuropathol Exp Neurol       Date:  2005-02       Impact factor: 3.685

Review 4.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

5.  A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics.

Authors:  B Cavalleri; H Pagani; G Volpe; E Selva; F Parenti
Journal:  J Antibiot (Tokyo)       Date:  1984-04       Impact factor: 2.649

Review 6.  Tau-targeting therapies for Alzheimer disease.

Authors:  Erin E Congdon; Einar M Sigurdsson
Journal:  Nat Rev Neurol       Date:  2018-07       Impact factor: 42.937

Review 7.  Genomic screening with RNAi: results and challenges.

Authors:  Stephanie Mohr; Chris Bakal; Norbert Perrimon
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

Review 8.  A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

Authors:  Eric Karran; John Hardy
Journal:  Ann Neurol       Date:  2014-07-02       Impact factor: 10.422

Review 9.  Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk.

Authors:  Anastasia G Efthymiou; Alison M Goate
Journal:  Mol Neurodegener       Date:  2017-05-26       Impact factor: 14.195

Review 10.  Mitochondria and Mitochondrial Cascades in Alzheimer's Disease.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more
  1 in total

Review 1.  Application of CRISPR/Cas9 in Alzheimer's Disease.

Authors:  Likui Lu; Xi Yu; Yongle Cai; Miao Sun; Hao Yang
Journal:  Front Neurosci       Date:  2021-12-21       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.